BioPharma Resources

Drug Trial Radar · NCT05079152

Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4

A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Wuhan) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)

Last checked: Nov 19, 2026Latest source record: Oct 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,404 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,404

Actual

Start

May 6, 2021

Primary completion

May 29, 2021

Study completion Dec 2021

Sponsor

Sponsor type
Industry
Collaborators
Chengdu Institute of Biological Products Co.,Ltd.; Changchun Institute of Biological Products Co., Ltd.; Wuhan Institute of Biological Products Co., Ltd; Hubei Provincial Center for Disease Control and Prevention; Guangdong Center for Disease Prevention and Control; Henan Center for Disease Control and Prevention
First posted
Oct 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Subjects will be recruited and divided into 3 groups: Experimental Group (468 subjects): 1st dose : combined vaccination of COVAX+PPV23, 2nd dose: combined vaccination of COVAX+IIV4; Control Group A (468 subjects): 1st dose: COVAX only, 2nd dose: COVAX only; Control Group B (468 subjects): 1st dose: PPV23 only, 2nd dose: IIV4 only. Blood samples will be collected 3 times: before the 1st dose of vaccinatioin; before the 2nd dose of vaccination; 28 days after the 2nd dose of vaccination. The immunogenicity and safety of both experimental and control groups will be analyzed.

Conditions

  • Influenza, Human
  • Pneumonia, Pneumococcal
  • COVID-19 Pneumonia

Interventions

  • COVAX+PPV23;COVAX+IIV4Biological

    1st dose : combined vaccination of COVAX+PPV23; 2nd dose: combined vaccination of COVAX+IIV4

  • COVAX only (1st and 2nd dose)Biological

    1st dose: COVAX only; 2nd dose: COVAX only

  • PPV23 for the 1st dose and IIV4 for the 2nd doseBiological

    1st dose: PPV23 only; 2nd dose: IIV4 only

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroconversion rate (COVAX)Time frame: Results obtained 28 days after the first dose (= right before the second dose)
  2. Seroconversion rate (COVAX)Time frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
  3. Neutralizing antibody level (COVAX)Time frame: Baseline (before vaccination) results
  4. Neutralizing antibody level (COVAX)Time frame: Results obtained 28 days after the first dose (= right before the second dose)
  5. Neutralizing antibody level (COVAX)Time frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
  6. Seropositive rate (IIV4)Time frame: Baseline (before vaccination) results
  7. Seroconversion rate (IIV4)Time frame: Results obtained 28 days after the first dose (= right before the second dose)
  8. Seroconversion rate (IIV4)Time frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
  9. Hemmagglution inhibition antibody level (IIV4)Time frame: Baseline (before vaccination) results
  10. Hemmagglution inhibition antibody level (IIV4)Time frame: Results obtained 28 days after the first dose (= right before the second dose)
  11. Hemmagglution inhibition antibody level (IIV4)Time frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
  12. Seroconversion rate (PPV23)Time frame: Results obtained 28 days after the first dose (= right before the second dose)
  13. Seroconversion rate (PPV23)Time frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
  14. Neutralizing antibody level (PPV23)Time frame: Baseline (before vaccination) results
  15. Neutralizing antibody level (PPV23)Time frame: Results obtained 28 days after the first dose (= right before the second dose)
  16. Neutralizing antibody level (PPV23)Time frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Guangdong Center for Disease Control and Prevention

    Guangzhou, Guangdong, China

  • Henan Center for Disease Control and Prevention

    Zhengzhou, Henan, China

  • Hubei Center for Disease Control and Prevention

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.